Advertisement

NK Cells

  • William Richard Childs
  • Jeremy M. Pantin
Reference work entry

Abstract

Natural killer (NK) cells are innate immune lymphocytes that express CD56 and lack CD3 surface antigens. NK cells do not require the presence of specific tumor antigen for the recognition and killing of cancer cells. NK cell recognition of tumor targets is regulated through a balance of activating and inhibitory signals. NK cells also have the ability to directly kill target cells through antibody-dependent cell cytotoxicity (ADCC) via the membrane Fc-γ receptor III (CD16) which binds to IgG antibodies and can also indirectly induce tumor apoptosis through cytokine secretion, directly through the perforin-granzyme pathway, or through death-receptor ligands such as TRAIL or Fas ligand expressed on their cell surfaces.

Tumors with low HLA class I expression are more susceptible to NK cell cytotoxicity. Adoptive infusion of allogeneic NK cells in patients who lack MHC class I molecules for one or more KIRs present in the donor may overcome NK cell-mediated KIR inactivation. Agents that increase surface expression of cellular death-receptors which render tumors more susceptible to NK cell cytotoxicity include bortezomib and depsipeptide. In vitro expanded autologous NK cells isolated from patients with cancers have been shown to exhibit significantly more cytotoxicity when tumors were pretreated with bortezomib compared with untreated tumor controls. Combining adoptive NK cell transfer with monoclonal antibody therapy could augment NK cell-mediated ADCC.

Keywords

Antibody-dependent cell cytotoxicity (ADCC) Chimeric antigen receptors (CAR) Interleukin-2 (IL-2) Killer immunoglobulin-like receptors (KIRs) Natural killer (NK) cells ADCC CAR Clinical trials Effector assessment IL-2 activation In cancer In vitro and in vivo susceptibility KIR-mediated inactivation of Tumor susceptibility 

References

  1. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 2003;24:603–9.CrossRefPubMedGoogle Scholar
  2. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32.CrossRefPubMedGoogle Scholar
  3. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med. 1995;181:1235–8.CrossRefPubMedGoogle Scholar
  4. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9.CrossRefPubMedGoogle Scholar
  5. Berg M, Lundqvist A, McCoy Jr P, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341–55.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008;180:6392–401.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bjorkstrom NK, Fauriat C, Bryceson YT, Sandberg JK, Ljunggren HG, Malmberg KJ. Analysis of the KIR repertoire in human NK cells by flow cytometry. Methods Mol Biol. 2010;612:353–64.CrossRefPubMedGoogle Scholar
  8. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33:1255–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Borrego F, Kabat J, Kim DK, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38:637–60.CrossRefPubMedGoogle Scholar
  10. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Elishmereni M, Bachelet I, Levi-Schaffer F. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders. Curr Opin Investig Drugs. 2008;9:491–6.PubMedGoogle Scholar
  12. Furutani E, Su S, Smith A, Berg M, Childs R. siRNA Inactivation of the inhibitory receptor NKG2A augments the anti-tumor effects of adoptively transferred NK cells in tumor-bearing hosts. ASH Annual Meeting Abstract 116; 2010, p. 1015.Google Scholar
  13. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.Google Scholar
  14. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003;88:1002–12.PubMedGoogle Scholar
  15. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28:571–80.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Iguchi-Manaka A, Kai H, Yamashita Y, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med. 2008;205:2959–64.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–9.CrossRefPubMedGoogle Scholar
  18. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol. 1999;163:1906–13.PubMedGoogle Scholar
  19. Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A. 2008;105:17481–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell. 1998;92:705–7.CrossRefPubMedGoogle Scholar
  21. Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol. 2000;61:7–17.CrossRefPubMedGoogle Scholar
  22. Lundqvist A, Abrams SI, Schrump DS, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:7317–25.CrossRefPubMedGoogle Scholar
  23. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009;113:6120–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.CrossRefPubMedGoogle Scholar
  25. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol. 2002;20:853–85.CrossRefPubMedGoogle Scholar
  26. Ramanathan M, Su S, Lundqvist A, et al. Lentiviral transduction of ex vivo expanded natural killer cells with a CD19 chimeric antigen receptor induces cytotoxicity against resistant B cell malignancies. ASH Ann Meet Abstr. 2008;112:3540.Google Scholar
  27. Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667–77.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28:955–959.Google Scholar
  29. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 2003;102:303–10.CrossRefPubMedGoogle Scholar
  30. Shiokawa M, Takahashi T, Murakami A, et al. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun. 2010;399:733–737.Google Scholar
  31. Smyth MJ, Thia KY, Cretney E, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162:6658–62.PubMedGoogle Scholar
  32. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy. 2008;10:775–83.CrossRefPubMedGoogle Scholar
  33. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53:279–87.CrossRefPubMedGoogle Scholar
  34. Sulica A, Morel P, Metes D, Herberman RB. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol. 2001;20:371–414.CrossRefPubMedGoogle Scholar
  35. Sun PD. Structure and function of natural-killer-cell receptors. Immunol Res. 2003;27:539–48.CrossRefPubMedGoogle Scholar
  36. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol. 2002;168:671–9.CrossRefPubMedGoogle Scholar
  37. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16:533–542.Google Scholar
  38. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res. 2010;29:134.Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Hematology Branch, National Heart, Lung, and Blood InstituteBethesdaUSA

Personalised recommendations